revlimid (▼) 15 mg/1 kapsula kapsula, tvrda
amicus pharma d.o.o. - lenalidomid - kapsula, tvrda - 15 mg/1 kapsula - 1 kapsula sadrži: 15 mg lenalidomida
revlimid (▼) 25 mg/1 kapsula kapsula, tvrda
amicus pharma d.o.o. - lenalidomid - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula sadrži: 25 mg lenalidomida
revlimid 15mg kapsula, tvrda
"evropa lek pharma" doo podgorica - lenalidomid - kapsula, tvrda - 15mg
revlimid 25mg kapsula, tvrda
"evropa lek pharma" doo podgorica - lenalidomid - kapsula, tvrda - 25mg
revlimid 2.5mg kapsula, tvrda
"evropa lek pharma" doo podgorica - lenalidomid - kapsula, tvrda - 2.5mg
revlimid 5mg kapsula, tvrda
"evropa lek pharma" doo podgorica - lenalidomid - kapsula, tvrda - 5mg
revlimid 10mg kapsula, tvrda
"evropa lek pharma" doo podgorica - lenalidomid - kapsula, tvrda - 10mg
kyprolis
amgen europe b.v. - carfilzomib - multipli mijelom - antineoplastična sredstva - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
ninlaro
takeda pharma a/s - ixazomib citrat - multipli mijelom - antineoplastična sredstva - ninlaro u kombinaciji s lenalidomidom i deksametazonom je indiciran za liječenje odraslih bolesnika s multiplim mijelom koji su primili najmanje jednu prethodnu terapiju.
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).